Anle138b modulates α-synuclein oligomerization and prevents motor decline and neurodegeneration in a mouse model of multiple system atrophy
2019 | journal article; research paper. A publication with affiliation to the University of Göttingen.
Jump to: Cite & Linked | Documents & Media | Details | Version history
Cite this publication
Anle138b modulates α-synuclein oligomerization and prevents motor decline and neurodegeneration in a mouse model of multiple system atrophy
Heras-Garvin, A.; Weckbecker, D.; Ryazanov, S.; Leonov, A.; Griesinger, C. ; Giese, A. & Wenning, G. K. et al. (2019)
Movement Disorders, 34(2) pp. 255-263. DOI: https://doi.org/10.1002/mds.27562
Documents & Media
Details
- Authors
- Heras-Garvin, Antonio; Weckbecker, Daniel; Ryazanov, Sergey; Leonov, Andrei; Griesinger, Christian ; Giese, Armin; Wenning, Gregor K.; Stefanova, Nadia
- Abstract
- MSA is a fatal neurodegenerative disease characterized by autonomic failure and severe motor impairment. Its main pathological hallmark is the accumulation of α-synuclein in oligodendrocytes, leading to glial and neuronal dysfunction and neurodegeneration. These features are recapitulated in the PLP-hαSyn mouse model expressing human α-synuclein in oligodendrocytes. At present, there is no effective disease-modifying therapy. Previous experiments have shown that the aggregation inhibitor, anle138b, reduces neurodegeneration and behavioral deficits in mouse models of other proteinopathies.
- Issue Date
- 2019
- Journal
- Movement Disorders
- Project
- EXC 2067: Multiscale Bioimaging
- Working Group
- RG Griesinger
- ISSN
- 0885-3185
- eISSN
- 1531-8257
- Language
- English